PHARMACOVIGILANCE
We maintain a commitment to our patients regarding the quality of the drugs we market.
It is important to report suspected adverse reactions after the drug has been authorized. It allows for continuous monitoring of the benefit-risk balance of the drug. Healthcare professionals and patients are encouraged to report any suspected adverse reactions through the following forms of contact.
National Center for Pharmacovigilance of the Ministry of Health of Panama.
Phone: +507 5129100
Email: fvigilancia@minsa.gob.pa
